NASDAQ:CNTX Context Therapeutics Q4 2024 Earnings Report $0.57 +0.01 (+1.58%) Closing price 04:00 PM EasternExtended Trading$0.60 +0.03 (+5.66%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Context Therapeutics EPS ResultsActual EPS-$0.04Consensus EPS -$0.05Beat/MissBeat by +$0.01One Year Ago EPSN/AContext Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AContext Therapeutics Announcement DetailsQuarterQ4 2024Date3/20/2025TimeBefore Market OpensConference Call DateWednesday, March 19, 2025Conference Call Time7:00PM ETUpcoming EarningsContext Therapeutics' Q1 2025 earnings is scheduled for Wednesday, August 6, 2025Conference Call ResourcesReportAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsReportAnnual report(10-K) Context Therapeutics Earnings HeadlinesContext Therapeutics Approves Reverse Stock Split AmendmentJune 12, 2025 | tipranks.comCo-Founder of Context Therapeutics Martin Lehr Buys 10% More SharesJune 11, 2025 | finance.yahoo.comTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.June 20, 2025 | Porter & Company (Ad)Context Therapeutics: Undervalued Cancer FighterJune 11, 2025 | seekingalpha.comContext Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO MeetingJune 2, 2025 | globenewswire.comContext Therapeutics Inc.: Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical OfficerMay 29, 2025 | finanznachrichten.deSee More Context Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email. Email Address About Context TherapeuticsContext Therapeutics (NASDAQ:CNTX), a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.View Context Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Citigroup (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
